LIRIMILAST
中文名称 | LIRIMILAST |
---|---|
中文同义词 | 化合物 T15766 |
英文名称 | LIRIMILAST |
英文同义词 | BAY 19-8004;LIRIMILAST;METHANESULFONIC ACID 2-(2,4-DICHLORO-BENZOYL)-3-UREIDO-BENZOFURAN-6-YL ESTER;UREA, N-[2-(2,4-DICHLOROBENZOYL)-6-[(METHYLSULFONYL)OXY]-3-BENZOFURANYL]-;Urea,[2-(2,4-dichlorobenzoyl)-6-[(methylsulfonyl)oxy]-3-benzofuranyl]-;BAY 19-8004 - Lirimilast |
CAS号 | 329306-27-6 |
分子式 | C17H12Cl2N2O6S |
分子量 | 443.26 |
EINECS号 | |
相关类别 | |
Mol文件 | 329306-27-6.mol |
结构式 | ![]() |
LIRIMILAST 性质
沸点 | 663.2±55.0 °C(Predicted) |
---|---|
密度 | 1.619±0.06 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 溶于二甲基亚砜 |
酸度系数(pKa) | 12.33±0.30(Predicted) |
PDE4 42 nM (IC 50 ) |
In PDE4 assays Lirimilast (BAY 19-8004) is reported to be 5-fold more potent than Cilomilast and equipotent with CDP-840 using freshly prepared PDE4 from human PMNL.
Since Lirimilast (BAY 19-8004) is orally active in the guinea-pig at 3 mg/kg and, more critically, in primates at 0.1 mg/kg/day it appears to have a good therapeutic ratio. In addition Lirimilast is found to be 3-fold more potent than Cilomilast when compared in a rat model of lung neutrophilic inflammation.
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-19672 | Lirimilast | 1 mg | 2240元 | |
2024/04/30 | HY-19672 | LIRIMILAST Lirimilast | 329306-27-6 | 5mg | 4480元 |